Nano Letters,
Journal Year:
2023,
Volume and Issue:
23(7), P. 2659 - 2668
Published: March 20, 2023
The
targeting
of
tumor
metabolism
as
a
novel
strategy
for
cancer
therapy
has
attracted
tremendous
attention.
Herein,
we
develop
dual
inhibitor,
Zn-carnosine
metallodrug
network
nanoparticles
(Zn-Car
MNs),
which
exhibits
good
Cu-depletion
and
Cu-responsive
drug
release,
causing
potent
inhibition
both
OXPHOS
glycolysis.
Notably,
Zn-Car
MNs
can
decrease
the
activity
cytochrome
c
oxidase
content
NAD+,
so
to
reduce
ATP
production
in
cells.
Thereby,
energy
deprivation,
together
with
depolarized
mitochondrial
membrane
potential
increased
oxidative
stress,
results
apoptosis
In
result,
exerted
more
efficient
metabolism-targeted
than
classic
copper
chelator,
tetrathiomolybdate
(TM),
breast
(sensitive
depletion)
colon
(less
sensitive
models.
efficacy
suggest
possibility
overcome
resistance
caused
by
metabolic
reprogramming
tumors
clinical
relevance.
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
35(33)
Published: March 7, 2023
Abstract
Immunotherapy
has
made
remarkable
strides
in
cancer
therapy
over
the
past
decade.
However,
such
emerging
still
suffers
from
low
response
rates
and
immune‐related
adverse
events.
Various
strategies
have
been
developed
to
overcome
these
serious
challenges.
Therein,
sonodynamic
(SDT),
as
a
non‐invasive
treatment,
received
ever‐increasing
attention
especially
treatment
of
deep‐seated
tumors.
Significantly,
SDT
can
effectively
induce
immunogenic
cell
death
trigger
systemic
anti‐tumor
immune
response,
termed
immunotherapy.
The
rapid
development
nanotechnology
revolutionized
effects
with
robust
induction.
As
result,
more
innovative
nanosonosensitizers
synergistic
modalities
are
established
superior
efficacy
safe
profile.
In
this
review,
recent
advances
immunotherapy
summarized
particular
emphasis
on
how
be
explored
harness
for
amplifying
response.
Moreover,
current
challenges
field
prospects
its
clinical
translation
also
presented.
It
is
anticipated
that
review
provide
rational
guidance
facilitate
nanomaterials‐assisted
immunotherapy,
helping
pave
way
next‐generation
eventually
achieve
durable
patients.
Advanced Materials,
Journal Year:
2022,
Volume and Issue:
34(35)
Published: April 26, 2022
Abstract
Ischemic
heart
disease
(IHD)
is
the
leading
cause
of
disability
and
mortality
worldwide.
Reactive
oxygen
species
(ROS)
have
been
shown
to
play
key
roles
in
progression
diabetes,
hypertension,
hypercholesterolemia,
which
are
independent
risk
factors
that
lead
atherosclerosis
development
IHD.
Engineered
biomaterial‐based
nanomedicines
under
extensive
investigation
exploration,
serving
as
smart
multifunctional
nanocarriers
for
synergistic
therapeutic
effect.
Capitalizing
on
cell/molecule‐targeting
drug
delivery,
present
enhanced
specificity
safety
with
favorable
pharmacokinetics
pharmacodynamics.
Herein,
ROS
both
IHD
its
discussed,
highlighting
cardiovascular
medications
antioxidant
properties,
summarizing
advantages,
recent
achievements
scavenging
capacity
treatment
atherosclerosis,
ischemia/reperfusion,
myocardial
infarction.
Finally,
current
challenges
ROS‐scavenging
possible
future
directions
discussed
from
a
clinical
perspective.
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
35(51)
Published: June 1, 2023
Sonodynamic
therapy
(SDT)
is
a
promising
non-invasive
therapeutic
modality
to
treat
deep-seated
tumors
owing
the
good
tissue
penetration
ability
and
spatiotemporal
controllability
of
ultrasound
(US);
however,
low
sonodynamic
activity
potential
side
effects
greatly
limit
its
clinical
translation.
Cancer
immunotherapy
that
leverages
immune
system
fight
against
cancer
has
great
synergize
with
SDT
for
treatment
high
efficiency
safety.
In
this
review,
convergence
exert
their
merits
break
through
limitations
combination
sono-immunotherapy
are
discussed.
The
focus
on
development
construction
organic
materials
immunotherapeutic
efficiency.
These
not
only
induce
immunogenic
cell
death
improve
tumor
immunogenicity
via
but
also
activate
antitumor
immunity
immuno-oncology
drug-mediated
pathway
modulation.
various
drugs
sonosensitizers
categorized
discussed
along
prospects
challenges
Advanced Materials,
Journal Year:
2022,
Volume and Issue:
35(10)
Published: Dec. 18, 2022
Conventional
sonodynamic
therapy
is
unavoidably
limited
by
the
tumor
microenvironment,
although
many
sonosensitizers
have
been
developed
to
improve
them
a
certain
extent.
Given
this,
concept
of
sonocatalytic
hydrogen
evolution
proposed,
which
defined
as
an
oxygen-independent
therapeutics.
To
demonstrate
feasibility
concept,
narrow-bandgap
semiconductor
bismuth
sulfide
(Bi2
S3
)
selected
sonocatalyst
and
platinum
(Pt)
nanoparticles
are
grown
in
situ
optimize
their
catalytic
performance.
In
this
nanocatalytic
system,
Pt
help
capture
sonoexcited
electrons,
whereas
intratumoral
overexpressed
glutathione
(GSH),
natural
hole
sacrificial
agent,
can
consume
holes,
greatly
improves
charge-separation
efficiency
promotes
controllable
sustainable
H2
generation.
Even
under
hypoxic
conditions,
Pt-Bi2
also
produce
sufficient
ultrasound
irradiation.
Mechanistically,
mitochondrial
dysfunction
caused
redox
homeostasis
destruction
GSH
depletion
synergistically
damage
DNA
induce
cells
apoptosis.
At
same
time,
holes
trigger
decomposition
peroxide
into
O2
relieve
hypoxia,
thus
being
synergistic
with
reverse
immunosuppressive
microenvironment.
The
proposed
sonocatalysis-mediated
will
provide
new
direction
realize
facile
efficient
cancer
therapy.
Chemical Society Reviews,
Journal Year:
2023,
Volume and Issue:
52(3), P. 973 - 1000
Published: Jan. 1, 2023
Lactate
in
tumors
has
long
been
considered
"metabolic
junk"
derived
from
the
glycolysis
of
cancer
cells
and
utilized
only
as
a
biomarker
malignancy,
but
is
presently
believed
to
be
pivotal
regulator
tumor
development,
maintenance
metastasis.
Indeed,
lactate
can
"fuel"
for
energy
supply
functions
signaling
molecule,
which
actively
contributes
progression,
angiogenesis,
immunosuppression,
therapeutic
resistance,
etc.,
thus
providing
promising
opportunities
treatment.
However,
current
approaches
regulating
homeostasis
with
available
agents
are
still
challenging,
mainly
due
short
half-life,
low
bioavailability
poor
specificity
these
their
unsatisfactory
outcomes.
In
recent
years,
modulation
nanomedicines
have
emerged
charming
efficient
strategy
fighting
cancer,
play
important
roles
optimizing
delivery
lactate-modulating
more
precise
effective
Integrating
specific
diverse
may
overcome
intrinsic
restrictions
different
modalities
by
remodeling
pathological
microenvironment
achieving
enhanced
therapy.
this
review,
most
advances
engineering
functional
that
modulate
therapy
summarized
discussed,
fundamental
mechanisms
benefits
various
therapeutics
elucidated.
Finally,
challenges
perspectives
emerging
anti-tumor
field
highlighted.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(12), P. 11537 - 11556
Published: June 5, 2023
Ferroptosis
activation
has
been
considered
a
mighty
weapon
for
cancer
treatment,
and
growing
attention
is
being
paid
to
reinforcing
tumor
cells'
sensitivity
ferroptosis.
However,
the
existence
of
certain
ferroptosis
resistance
mechanisms,
especially
abnormal
metabolism
cells,
long
underestimated.
We
propose
an
enhanced
ferroptosis-activating
pattern
via
regulating
glycometabolism
construct
nanoplatform
named
PMVL,
which
composed
lonidamine
(LND)-loaded
tannic
acid
coordinated
vanadium
oxides
with
camouflage
PD-L1
inhibiting
peptide-modified
cell
membrane.
This
work
reveals
that
mixed
valence
(VIV
VV)
in
PMVL
triggers
due
self-cyclic
alteration
V,
process
generates
•OH
lipid
peroxide
accumulation
→
depletes
glutathione
(GSH)
peroxidase
(GPX4)
deactivation
(VV
VIV).
Notably,
LND
strengthens
by
dual
suppression
glycolysis
(decreasing
ATP
supply)
pentose
phosphate
pathway
NADPH
production),
causing
anabatic
GSH
consumption.
Besides,
inhibited
less
intracellular
lactic
alleviates
acidity
microenvironment,
preventing
immunosuppressive
M2
macrophage
polarization.
In
vitro
vivo
data
demonstrate
glycometabolism-intervention-enhanced
boosted
immunity
activation,
potentially
providing
opportunities
possibilities
synergetic
therapy.
Chemical Society Reviews,
Journal Year:
2024,
Volume and Issue:
53(5), P. 2643 - 2692
Published: Jan. 1, 2024
This
review
discusses
the
structures
and
engineering
strategies
of
nanocatalysts,
highlighting
their
underlying
mechanisms
applications
in
cancer
immunotherapy.
